Y-mAbs Therapeutics, Inc (NASDAQ:YMAB)
| 51.23 Delayed Data As of 3:59pm ET |  +0.47 / +0.93%Today’s Change | 14.16 Today|||52-Week Range 55.22 | +63.94% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $1.9B |
Company Description
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Contact Information
Y-mAbs Therapeutics, Inc. 230 Park Avenue New York New York 10169 |
Employees
Shareholders
| Mutual fund holders | 33.61% |
| Individual stakeholders | 27.47% |
| Other institutional | 22.17% |
Top Executives
| Thomas Gad | Chairman, President & Head-Business Development |
| Claus Juan Møller-San Pedro | Chief Executive Officer & Director |
| Joris Wiel Jan Wilms | Chief Operating Officer & Senior Vice President |
| Bo Kruse | CFO, Secretary. Treasurer & Executive VP |
| Torben Lund-Hansen | Chief Technology Officer & Senior Vice President |
